Cargando…

Risk of interstitial lung disease in patients treated for atrial fibrillation with dronedarone versus other antiarrhythmics

PURPOSE: To compare risks of interstitial lung disease (ILD) between patients treated with dronedarone versus other antiarrhythmics. METHODS: Parallel retrospective cohort studies were conducted in the United States Department of Defense Military Health System database (DoD) and the HealthCore Integ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tave, Arlene, Goehring, Earl, Desai, Vibha, Wu, Chuntao, Bohn, Rhonda L., Tamayo, Sally G., Sicignano, Nicholas, Juhaeri, Juhaeri, Jones, Judith K., Weiss, Sheila R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453764/ https://www.ncbi.nlm.nih.gov/pubmed/33730412 http://dx.doi.org/10.1002/pds.5233

Ejemplares similares

Pleiotropic Effects of Antiarrhythmic Agents: Dronedarone in the Treatment of Atrial Fibrillation
por: Heijman, Jordi, et al.
Publicado: (2013)

Dronedarone in the management of atrial fibrillation
por: Saleem, TS Mohamed, et al.
Publicado: (2010)

International cohort study on the effectiveness of dronedarone and other antiarrhythmic drugs for atrial fibrillation in real-world practice (EFFECT-AF)
por: Khachatryan, Artak, et al.
Publicado: (2021)

Benefit–risk evaluation: the past, present and future
por: Juhaeri, Juhaeri
Publicado: (2019)

Management of atrial fibrillation: focus on the role of dronedarone
por: Cheng, Judy WM
Publicado: (2011)

Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy
por: Wolbrette, Deborah, et al.
Publicado: (2010)

Impact of dronedarone in atrial fibrillation and flutter on stroke reduction
por: Christiansen, Christine Benn, et al.
Publicado: (2010)

Dronedarone for atrial fibrillation: a new therapeutic agent
por: Patel, Pawan D, et al.
Publicado: (2009)

Cost considerations in the management of atrial fibrillation – impact of dronedarone
por: Khaykin, Yaariv, et al.
Publicado: (2012)

Managing atrial fibrillation in the elderly: critical appraisal of dronedarone
por: Trigo, Paula, et al.
Publicado: (2012)

Safety and Efficacy of Dronedarone in the Treatment of Atrial Fibrillation/Flutter
por: Naccarelli, Gerald V., et al.
Publicado: (2011)

Elevated liver enzymes associated with dronedarone for atrial fibrillation
por: Ragucci, Kelly R
Publicado: (2013)

Dronedarone-induced Phototoxicity in a Patient with Atrial Fibrillation
por: Datar, Praveen, et al.
Publicado: (2019)

Dronedarone attenuates the duration of atrial fibrillation in a dog model of sustained atrial fibrillation
por: Saengklub, Nakkawee, et al.
Publicado: (2017)

Emerging Antiarrhythmic Drugs for Atrial Fibrillation
por: Saljic, Arnela, et al.
Publicado: (2022)

The Role of Dronedarone in the Treatment of Atrial Fibrillation/Flutter in the Aftermath of PALLAS
por: Naccarelli, Gerald V, et al.
Publicado: (2014)

Performance assessment of different machine learning approaches in predicting diabetic ketoacidosis in adults with type 1 diabetes using electronic health records data
por: Li, Lin, et al.
Publicado: (2021)

Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation
por: Schweizer, Patrick A, et al.
Publicado: (2011)

Addressing the management of atrial fibrillation – a systematic review of the role of dronedarone
por: Podda, Gian Marco, et al.
Publicado: (2012)

Dronedarone: evidence supporting its therapeutic use in the treatment of atrial fibrillation
por: Sullivan, Renee M, et al.
Publicado: (2010)

Impact of controlling atrial fibrillation on outcomes relevant to the patient: focus on dronedarone
por: Chahal, C Anwar A, et al.
Publicado: (2012)

Cost-Effectiveness of Dronedarone and Amiodarone for the Treatment of Chinese Patients With Atrial Fibrillation
por: Zhang, Mengran, et al.
Publicado: (2021)

Amiodarone vs Dronedarone for Atrial Fibrillation: A Retrospective Cohort Study
por: Brophy, James M., et al.
Publicado: (2022)

Predicting the risk of end-stage renal disease in the population-based setting: a retrospective case-control study
por: Johnson, Eric S, et al.
Publicado: (2011)

Hypothesis-free signal detection in healthcare databases: finding its value for pharmacovigilance
por: Bate, Andrew, et al.
Publicado: (2019)

Class III antiarrhythmic drugs amiodarone and dronedarone impair K(IR)2.1 backward trafficking
por: Ji, Yuan, et al.
Publicado: (2017)

Impact of Dronedarone Treatment on Healthcare Resource Utilization in Patients with Atrial Fibrillation/Flutter
por: Kim, Michael H., et al.
Publicado: (2014)

Antiarrhythmic drugs for atrial fibrillation: Imminent impulses are emerging
por: Dan, Gheorghe-Andrei, et al.
Publicado: (2018)

Oral Anticoagulation and Antiarrhythmic Drug Therapy for Atrial Fibrillation
por: Reiffel, James A.
Publicado: (2018)

Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study
por: Torp-Pedersen, Christian, et al.
Publicado: (2011)

Efficacy and safety of dronedarone by atrial fibrillation history duration: Insights from the ATHENA study
por: Blomström‐Lundqvist, Carina, et al.
Publicado: (2020)

Comparative Safety and Effectiveness of Sotalol Versus Dronedarone After Catheter Ablation for Atrial Fibrillation
por: Wharton, John Marcus, et al.
Publicado: (2022)

Prior antiarrhythmic drug use and the outcome of atrial fibrillation ablation
por: Winkle, Roger A., et al.
Publicado: (2012)

Computational Modeling for Antiarrhythmic Drugs for Atrial Fibrillation According to Genotype
por: Hwang, Inseok, et al.
Publicado: (2021)

Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies
por: Naccarelli, Gerald V., et al.
Publicado: (2020)

Correction to: Comparative Safety and Effectiveness of Sotalol Versus Dronedarone After Catheter Ablation for Atrial Fibrillation
Publicado: (2022)

Structured benefit–risk evaluation for medicinal products: review of quantitative benefit–risk assessment findings in the literature
por: Kürzinger, Marie-Laure, et al.
Publicado: (2020)

Efficacy of class III antiarrhythmics and magnesium combination therapy for atrial fibrillation
por: Wang, Amy
Publicado: (2012)

Time‐dependent antiarrhythmic effects of flecainide on induced atrial fibrillation in horses
por: Carstensen, Helena, et al.
Publicado: (2018)

Knots to untie: anticoagulant and antiarrhythmic therapy after ablation for atrial fibrillation
por: Stazi, Filippo
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_he0dchbgkle08b3vkrb1dv9lmu